A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples